Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    March 2017
  1. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  2. IMAFUKU K, Yoshino K, Yamaguchi K, Tsuboi S, et al
    Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  3. RUSHTON L, Hutchings SJ
    Reply to 'Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'' - outdoor occupation may not be linked to increased risk of melanoma in Britain.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  4. GRANT WB
    Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  5. KINSLER VA, O'Hare P, Jacques T, Hargrave D, et al
    MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  6. DAUD A, Kluger HM, Kurzrock R, Schimmoller F, et al
    Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  7. RUSHTON L, Hutchings SJ
    The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  8. DALY LE, Power DG, O'Reilly A, Donnellan P, et al
    The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  9. HUBNER J, Waldmann A, Geller AC, Weinstock MA, et al
    Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  10. LI X, Liang L, Feng YA, De Vivo I, et al
    Height, height-related SNPs, and risk of non-melanoma skin cancer.
    Br J Cancer. 2016 Nov 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  11. KAUR A, Webster MR, Weeraratna AT
    In the Wnt-er of life: Wnt signalling in melanoma and ageing.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  12. CARLINO MS, Vanella V, Girgis C, Giannarelli D, et al
    Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  13. GUPTA A, Roberts C, Tysoe F, Goff M, et al
    RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  14. KHOJA L, Kibiro M, Metser U, Gedye C, et al
    Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  15. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  16. AWAIS R, Spiller DG, White MR, Paraoan L, et al
    p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma.
    Br J Cancer. 2016 Sep 1. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  17. POTTEGARD A, Schmidt SA, Olesen AB, Achacoso N, et al
    Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  18. RAJKUMAR S, Watson IR
    Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  19. LO MC, Paterson A, Maraka J, Clark R, et al
    A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  20. MOURIAUX F, Servois V, Parienti JJ, Lesimple T, et al
    Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  21. LE TOURNEAU C, Dreno B, Kirova Y, Grob JJ, et al
    First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.
    Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    April 2016
  22. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
    Br J Cancer. 2016 Apr 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  23. LOSKOG A, Maleka A, Mangsbo S, Svensson E, et al
    Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.
    Br J Cancer. 2016 Mar 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  24. TATE SC, Burke TF, Hartman D, Kulanthaivel P, et al
    Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    Br J Cancer. 2016;114:669-79.
    PubMed     Text format     Abstract available


    February 2016
  25. HUGDAHL E, Kalvenes MB, Puntervoll HE, Ladstein RG, et al
    BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Br J Cancer. 2016 Feb 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  26. CARTER JH, Deddens JA, Spaulding Iv NR, Lucas D, et al
    Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma.
    Br J Cancer. 2016;114:444-53.
    PubMed     Text format     Abstract available


    January 2016
  27. DIEM S, Kasenda B, Spain L, Martin-Liberal J, et al
    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  28. WANG A, Stefanick ML, Kapphahn K, Hedlin H, et al
    Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.
    Br J Cancer. 2016 Jan 7. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  29. AMIROUCHENE-ANGELOZZI N, Schoumacher M, Stern MH, Cassoux N, et al
    Upcoming translational challenges for uveal melanoma.
    Br J Cancer. 2015;113:1746.
    PubMed     Text format    


  30. PICH C, Sarrabayrouse G, Teiti I, Mariame B, et al
    Melanoma-expressed CD70 is involved in invasion and metastasis.
    Br J Cancer. 2015 Dec 15. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    October 2015
  31. SIRET C, Terciolo C, Dobric A, Habib MC, et al
    Interplay between cadherins and alpha2beta1 integrin differentially regulates melanoma cell invasion.
    Br J Cancer. 2015 Oct 29. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  32. NABIL AA, Marie S, Marc-Henri S, Nathalie C, et al
    Upcoming translational challenges for uveal melanoma.
    Br J Cancer. 2015 Oct 27. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  33. WILKINS A, Furness A, W Corbett R, Bloomfield A, et al
    The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
    Br J Cancer. 2015 Oct 20. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    July 2015
  34. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


    June 2015
  35. TAGLIABUE E, Fargnoli MC, Gandini S, Maisonneuve P, et al
    MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.
    Br J Cancer. 2015 Jun 23. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  36. EL HAJJ P, Gilot D, Migault M, Theunis A, et al
    SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.
    Br J Cancer. 2015 Jun 11. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    May 2015
  37. FERRUCCI PF, Gandini S, Battaglia A, Alfieri S, et al
    Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
    Br J Cancer. 2015 May 26. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  38. SRIVASTAVA SK, Bhardwaj A, Arora S, Tyagi N, et al
    Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis.
    Br J Cancer. 2015 May 5. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    April 2015
  39. ALGAZI AP, Cha E, Ortiz-Urda SM, McCalmont T, et al
    The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
    Br J Cancer. 2015;112:1326-31.
    PubMed     Text format     Abstract available


    March 2015
  40. RUTHERFORD MJ, Ironmonger L, Ormiston-Smith N, Abel GA, et al
    Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma.
    Br J Cancer. 2015 Mar 3. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    February 2015
  41. BAGNARDI V, Rota M, Botteri E, Tramacere I, et al
    Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis.
    Br J Cancer. 2015;112:580-93.
    PubMed     Text format     Abstract available


    November 2014
  42. WARD ST, Li KK, Hepburn E, Weston CJ, et al
    The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.
    Br J Cancer. 2014 Nov 18. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    October 2014
  43. LA ROSA F, Liso A, Bianconi F, Duca E, et al
    Seasonal variation in the month of birth in patients with skin cancer.
    Br J Cancer. 2014;111:1810-3.
    PubMed     Text format     Abstract available


  44. HEINZERLING L, Schuler G, Hartmann A, Schneider-Stock R, et al
    Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
    Br J Cancer. 2014;111:1679-80.
    PubMed     Text format    


  45. MENZIES AM, Wilmott JS, Long GV, Scolyer RA, et al
    Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
    Br J Cancer. 2014;111:1678-9.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: